TP53 and endometrial cancer: Given that 80% of endometrial cancers do not harbor TP53 mutations, understanding the EC-specific impact of this pathway could create an opportunity to improve radiotherapy prescription on both sides of the mutational spectrum (wild type and/or aberrant).